|
May 14
|
The Strong Earnings Posted By Catalyst Pharmaceuticals (NASDAQ:CPRX) Are A Good Indication Of The Strength Of The Business
|
|
Apr 11
|
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts?
|
|
Apr 11
|
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
|
|
Apr 9
|
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip
|
|
Apr 8
|
Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade
|
|
Apr 8
|
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
|
|
Feb 26
|
Catalyst: Q4 Earnings Snapshot
|
|
Feb 26
|
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
|
|
Feb 18
|
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
|
|
Feb 18
|
Incyte Stock Sees Relative Strength Rating Rise To 71
|
|
Feb 17
|
Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 374%
|
|
Feb 12
|
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
|
|
Jan 3
|
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
|
|
Oct 17
|
High Growth Tech Stocks to Watch in October 2024
|
|
Oct 1
|
Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Oct 1
|
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
|
|
Sep 6
|
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
|
|
Sep 2
|
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
|
|
Jul 24
|
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
|
|
Jul 22
|
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
|